BR112014003445A2 - métodos para melhora de sintomas ou condições causadas por estresse - Google Patents

métodos para melhora de sintomas ou condições causadas por estresse

Info

Publication number
BR112014003445A2
BR112014003445A2 BR112014003445A BR112014003445A BR112014003445A2 BR 112014003445 A2 BR112014003445 A2 BR 112014003445A2 BR 112014003445 A BR112014003445 A BR 112014003445A BR 112014003445 A BR112014003445 A BR 112014003445A BR 112014003445 A2 BR112014003445 A2 BR 112014003445A2
Authority
BR
Brazil
Prior art keywords
stress
methods
conditions caused
symptoms
improving symptoms
Prior art date
Application number
BR112014003445A
Other languages
English (en)
Inventor
Tissot-Favre Delphine
Pan Yuanlong
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of BR112014003445A2 publication Critical patent/BR112014003445A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Birds (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)

Abstract

resumo patente de invenção: "métodos para melhora de sintomas ou condições causadas por estresse". a presente invenção refere-se a métodos para uso de alcanolamidas de ácido graxo para melhorar um ou mais sintomas ou condições causados por estresse, por exemplo, perda de apetite, ou para manter e intensificar entrada de nutriente e entrada calórica por um animal sob estresse, ou que tenha experimentado estresse. geralmente, as alcanolamidas de ácido graxo em quantidades de a partir de cerca de 0,1 a cerca de 1500 mg/kg/dia antes, durante ou após estresse, preferivelmente em uma base regular ou diária como um componente de uma composição de alimentação, ou como um suplemento dietético.
BR112014003445A 2011-08-15 2012-08-07 métodos para melhora de sintomas ou condições causadas por estresse BR112014003445A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161575073P 2011-08-15 2011-08-15
PCT/US2012/049825 WO2013025399A1 (en) 2011-08-15 2012-08-07 Methods for ameliorating symptoms or conditions caused by stress

Publications (1)

Publication Number Publication Date
BR112014003445A2 true BR112014003445A2 (pt) 2018-03-20

Family

ID=47715371

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014003445A BR112014003445A2 (pt) 2011-08-15 2012-08-07 métodos para melhora de sintomas ou condições causadas por estresse

Country Status (10)

Country Link
US (1) US20140199267A1 (pt)
EP (1) EP2744488A4 (pt)
JP (1) JP2014525931A (pt)
CN (1) CN103917230A (pt)
AU (1) AU2012295432A1 (pt)
BR (1) BR112014003445A2 (pt)
CA (1) CA2846213A1 (pt)
MX (1) MX2014001767A (pt)
RU (1) RU2014110056A (pt)
WO (1) WO2013025399A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110178151A1 (en) 2008-03-04 2011-07-21 Yissum Research Development Company Of The Hebrew Compounds and methods of treating obesity
WO2014013497A1 (en) * 2012-07-20 2014-01-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Fatty acid derivatives for use in a method of treating depression and associated conditions
JP6563218B2 (ja) * 2015-03-13 2019-08-21 ユニ・チャーム株式会社 ペットフードの製造方法
KR101997028B1 (ko) * 2018-11-30 2019-07-05 강원대학교산학협력단 각성 강화용 유산균 혼합 조성물 및 이의 용도
JP7072965B2 (ja) * 2019-12-02 2022-05-23 株式会社ライフ・クオリティ研究所 ストレス障害の予防又は改善用剤及びそれを含む組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923738D0 (en) * 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
US20090082435A1 (en) * 2005-04-28 2009-03-26 The Regents Of The University Of California Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders
US20070155747A1 (en) * 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
CN101351495A (zh) * 2005-12-29 2009-01-21 欧加农股份有限公司 脂肪酸酰胺水解酶抑制剂
WO2008030752A2 (en) * 2006-09-07 2008-03-13 N.V. Organon Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
RU2496487C2 (ru) * 2008-05-19 2013-10-27 Нестек С.А. Способы снижения абсорбции липидов у животных
US20100190860A1 (en) * 2009-01-09 2010-07-29 The Brigham And Women's Hospital, Inc. Methods for selectively enhancing antinociceptive potency of local anesthetics

Also Published As

Publication number Publication date
EP2744488A4 (en) 2014-07-09
EP2744488A1 (en) 2014-06-25
CA2846213A1 (en) 2013-02-21
JP2014525931A (ja) 2014-10-02
US20140199267A1 (en) 2014-07-17
MX2014001767A (es) 2014-05-01
CN103917230A (zh) 2014-07-09
WO2013025399A1 (en) 2013-02-21
RU2014110056A (ru) 2015-09-27
AU2012295432A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
WO2013153071A3 (en) A nutritional composition
BR112014010958A2 (pt) processos com base na membrana para a redução de pelo menos uma impureza e preparação de um concentrado compreendendo pelo menos um componente natural a partir de uma mistura de óleo de ácido graxo não marinho, e suas composições resultantes
BR112014003445A2 (pt) métodos para melhora de sintomas ou condições causadas por estresse
EA201070419A1 (ru) Состав для регулирования метаболизма липидов
NZ778131A (en) Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
MX342733B (es) Composicion nutricional para promover el desarrollo y crecimiento sano.
BR112012020160A2 (pt) liga, método de fabricar uma peça fundida e peça fundida.
BRPI0914321A2 (pt) processo de avaliação da quantidade de metano produzida por um ruminante leiteiro e processo para diminuir e controlar essa quantidade
MY165142A (en) Metabolic imprinting effects of specifically designed lipid component
WO2013049519A3 (en) Compositions, kits and methods for nutritional supplementation with twelve carbon chain fatty acids and twelve carbon chain acylglycerols
BR112013020346A2 (pt) concentrado de ácido eicosapentaenoico, produto farmac~eutico, método de elaboração de um concentrado de ácido eicosapentaenoico e uso de óleo microbiano
BR112014016033A8 (pt) processo para isolamento de uma composição de proteína e uma composição de gordura de aves domésticas mecanicamente desossadas
CL2013001386A1 (es) Conjunto de composiciones nutricionales para lactantes que comprende una primera composicion para lactantes de 0 a 4 semanas, una segunda composicion para lactantes de 4 a 8 semanas, y una tercera composicion para lactantes de 3 a 6 meses, cada una con distintas densidades caloricas; y su uso para reducir la obesidad, diabetes y enfermedades cardiovasculares posteriormente en la vida.
BR112012016726A2 (pt) "processo para isolar uma composição de proteínas e uma composição de gorduras de aparas de carne"
BR112014003640A8 (pt) métodos para perda de peso e composições cetogênicas
BR112014013483A2 (pt) análogo de insulina humana e derivado acilado do mesmo
BR112014009097A2 (pt) composição para uso na promoção de crescimento de osso saudável e/ou na prevenção e/ou tratamento das doenças dos ossos
RU2011144102A (ru) Снижение риска ожирения
MX351336B (es) Uso de aguacates blandos enteros para obtener un aceite de aguacate rico en masa no saponificable.
BR112012029269A2 (pt) aglutinante de micotoxina para alimentos de animal.
BR112012027427A2 (pt) composições nutritivas e métodos para a mudança da nutrição parenteral para a nutrição enteral
RU2012139658A (ru) Композиции и способы для доставки питательных веществ
PH12018500035A1 (en) Nutritional compositions and methods for promoting cognitive development
BR112013018298A2 (pt) compostos para a redução da produção de beta-amiloides
BR112014027738A2 (pt) ácido graxo de talóleo que é modificado por saponificação para uso, suplemento alimentar, e composto alimentar

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2476 DE 19/06/2018.